Verano Holdings (VRNO) Change in Account Payables (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Change in Account Payables of -$5.7 million for Q1 2026, down 175.52% year-over-year from $7.6 million in Q1 2025, and down 329.87% quarter-over-quarter from -$1.3 million in Q4 2025.
Verano Holdings (VRNO) Change in Account Payables (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Change in Account Payables for 6 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 175.52% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at -$7.9 million (down 206.61% YoY), while the FY2025 annual figure was $5.4 million, up 228.5% from the prior year.
- Change in Account Payables slipped to -$5.7 million in Q1 2026 per VRNO's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $19.9 million in Q1 2022 and bottomed at -$13.7 million in Q4 2022.
- Historically, Change in Account Payables has averaged -$1.2 million across 5 years, with a median of -$3.0 million in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 2522.59% in 2024 and fell as far as 495.85% in 2024.
- Verano Holdings' Change in Account Payables stood at -$13.7 million in 2022, then jumped by 96.32% to -$506000.0 in 2023, then tumbled by 495.85% to -$3.0 million in 2024, then soared by 55.92% to -$1.3 million in 2025, then slumped by 329.87% to -$5.7 million in 2026.
- Business Quant data shows VRNO's Change in Account Payables at -$5.7 million in Q1 2026, -$1.3 million in Q4 2025, and $5.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn | -2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.38 Mn |
| Jun 30, 2026 | -2.38 Mn |
| Mar 31, 2026 | -5.71 Mn |
| Mar 31, 2026 | -5.71 Mn |
| Dec 31, 2025 | -1.33 Mn |
| Dec 31, 2025 | -1.33 Mn |
| Sep 30, 2025 | 5.35 Mn |
| Sep 30, 2025 | 5.35 Mn |
| Jun 30, 2025 | -6.21 Mn |
| Jun 30, 2025 | -6.21 Mn |
| Mar 31, 2025 | 7.57 Mn |
| Mar 31, 2025 | 7.57 Mn |
| Dec 31, 2024 | -3.02 Mn |
| Dec 31, 2024 | -3.02 Mn |
| Sep 30, 2024 | 8.71 Mn |
| Sep 30, 2024 | 8.71 Mn |
| Jun 30, 2024 | -5.84 Mn |
| Jun 30, 2024 | -5.84 Mn |
| Mar 31, 2024 | -4.03 Mn |
| Mar 31, 2024 | -4.03 Mn |